Agios Pharma (0HB0) Ratios
Agios Pharma Ratios
GB:0HB0's free cash flow for Q2 2026 was $-58.52M. For the 2026 fiscal year, GB:0HB0's free cash flow was decreased by $-1.21M and operating cash flow was $-57.31M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.46 | 11.90 | 12.27 | 13.30 | 17.79 |
| Quick Ratio | 11.06 | 11.56 | 11.99 | 13.16 | 17.79 |
| Cash Ratio | 1.08 | 0.94 | 1.30 | 2.22 | 3.40 |
| Solvency Ratio | -3.92 | 5.56 | -2.74 | -1.62 | 11.14 |
| Operating Cash Flow Ratio | -4.54 | -4.80 | -4.36 | -4.94 | -6.81 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 837.94M | $ 843.36M | $ 707.74M | $ 694.87M | $ 918.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 0.08 | 0.07 | 0.07 |
| Debt-to-Equity Ratio | 0.03 | 0.04 | 0.09 | 0.08 | 0.08 |
| Debt-to-Capital Ratio | 0.03 | 0.04 | 0.08 | 0.07 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.08 | 1.16 | 1.13 | 1.11 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.69 | 1.00 | 1.29 | 1.56 | 1.61 |
| Net Debt to EBITDA | 0.12 | -0.03 | 0.04 | 0.14 | 0.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 78.67% | 88.59% | 64.57% | 88.03% | 0.00% |
| EBIT Margin | -765.89% | 1967.15% | -1459.52% | -2732.07% | 0.00% |
| EBITDA Margin | -756.31% | 1982.63% | -1434.83% | -2671.93% | 0.00% |
| Operating Profit Margin | -873.87% | -1166.47% | -1459.52% | -2732.07% | 0.00% |
| Pretax Profit Margin | -765.89% | 1967.15% | -1312.63% | -1627.82% | 0.00% |
| Net Profit Margin | -764.01% | 1845.92% | -1312.63% | -1627.82% | 0.00% |
| Continuous Operations Profit Margin | -764.01% | 1845.92% | -1312.63% | -1627.82% | 0.00% |
| Net Income Per EBT | 99.75% | 93.84% | 100.00% | 100.00% | -450.12% |
| EBT Per EBIT | 87.64% | -168.64% | 89.94% | 59.58% | 94.21% |
| Return on Assets (ROA) | -31.82% | 40.51% | -37.57% | -18.71% | 111.61% |
| Return on Equity (ROE) | -34.60% | 43.72% | -43.41% | -21.06% | 124.21% |
| Return on Capital Employed (ROCE) | -38.86% | -26.91% | -45.04% | -33.08% | -27.46% |
| Return on Invested Capital (ROIC) | -38.18% | -24.99% | -44.28% | -32.70% | -27.24% |
| Return on Tangible Assets | -31.82% | 40.51% | -37.57% | -18.71% | 111.61% |
| Earnings Yield | -26.16% | 36.09% | -28.41% | -15.07% | 80.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.11 | 8.88 | 9.55 | 6.46 | 0.00 |
| Payables Turnover | 0.63 | 0.25 | 0.97 | 0.09 | 1.12 |
| Inventory Turnover | 0.35 | 0.15 | 0.50 | 0.20 | 0.00 |
| Fixed Asset Turnover | 1.31 | 0.67 | 0.38 | 0.16 | 0.00 |
| Asset Turnover | 0.04 | 0.02 | 0.03 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.06 | 0.04 | 0.03 | 0.02 | 0.00 |
| Cash Conversion Cycle | 532.85 | 1002.71 | 395.25 | -2112.04 | -324.63 |
| Days of Sales Outstanding | 71.46 | 41.09 | 38.24 | 56.54 | 0.00 |
| Days of Inventory Outstanding | 1042.86 | 2420.13 | 732.61 | 1819.00 | 0.00 |
| Days of Payables Outstanding | 581.46 | 1458.51 | 375.60 | 3987.58 | 324.63 |
| Operating Cycle | 1114.31 | 2461.22 | 770.85 | 1875.55 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.43 | -6.86 | -5.32 | -5.65 | -6.74 |
| Free Cash Flow Per Share | -6.51 | -6.89 | -5.34 | -5.74 | -6.83 |
| Dividend Paid and CapEx Coverage Ratio | -86.42 | -231.36 | -296.36 | -63.40 | -70.95 |
| Capital Expenditure Coverage Ratio | -86.42 | -231.36 | -296.36 | -63.40 | -70.95 |
| Operating Cash Flow Coverage Ratio | -9.28 | -6.84 | -4.11 | -3.61 | -4.20 |
| Operating Cash Flow to Sales Ratio | -6.90 | -10.68 | -11.04 | -21.73 | 0.00 |
| Free Cash Flow Yield | -23.91% | -20.97% | -23.97% | -20.43% | -20.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.82 | 2.77 | -3.52 | -6.64 | 1.24 |
| Price-to-Sales (P/S) Ratio | 29.21 | 51.14 | 46.21 | 108.04 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.32 | 1.21 | 1.53 | 1.40 | 1.54 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.18 | -4.77 | -4.17 | -4.89 | -4.81 |
| Price-to-Operating Cash Flow Ratio | -4.23 | -4.79 | -4.19 | -4.97 | -4.88 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.01 | -0.07 | 0.20 | 0.04 |
| Enterprise Value Multiple | -3.74 | 2.55 | -3.18 | -3.90 | -5.57 |
| Enterprise Value | 1.53B | 1.85B | 1.22B | 1.48B | 1.88B |
| EV to EBITDA | -3.74 | 2.55 | -3.18 | -3.90 | -5.57 |
| EV to Sales | 28.30 | 50.62 | 45.60 | 104.28 | 0.00 |
| EV to Free Cash Flow | -4.05 | -4.72 | -4.12 | -4.72 | -4.55 |
| EV to Operating Cash Flow | -4.10 | -4.74 | -4.13 | -4.80 | -4.62 |
| Tangible Book Value Per Share | 20.58 | 27.13 | 14.57 | 20.09 | 21.37 |
| Shareholders’ Equity Per Share | 20.58 | 27.13 | 14.57 | 20.09 | 21.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.93 | 0.64 | 0.48 | 0.26 | 0.00 |
| Net Income Per Share | -7.12 | 11.86 | -6.33 | -4.23 | 26.55 |
| Tax Burden | 1.00 | 0.94 | 1.00 | 1.00 | -4.50 |
| Interest Burden | 1.00 | 1.00 | 0.90 | 0.60 | 1.00 |
| Research & Development to Revenue | 6.19 | 8.25 | 10.77 | 19.66 | 0.00 |
| SG&A to Revenue | 3.34 | 4.30 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.97 | 1.17 | 1.67 | 3.46 | 0.00 |
| Income Quality | 0.90 | -0.58 | 0.84 | 1.34 | 1.14 |
Currency in USD